Regeneron Pharmaceuticals, Inc. (REGN)
$
634.23
-3.13 (-0.49%)
Key metrics
Financial statements
Free cash flow per share
33.4312
Market cap
68.5 Billion
Price to sales ratio
4.8248
Debt to equity
0.0568
Current ratio
33.4544
Income quality
1.0018
Average inventory
3.1 Billion
ROE
0.1477
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Regeneron Pharmaceuticals, Inc. is engaged in the discovery, invention, development, manufacturing, and commercialization of medicines for a range of diseases globally. The operating income ratio is 0.28 indicating the company's operational profitability margin. Its diverse product range includes EYLEA, which is used to treat conditions such as wet age-related macular degeneration and diabetic macular edema, alongside treatments for myopic choroidal neovascularization and various forms of diabetic retinopathy. The company also develops and markets Dupixent for atopic dermatitis and asthma in both adults and children, Libtayo for specific cancers, and Praluent for managing familial hypercholesterolemia and cardiovascular disease. Moreover, REGEN-COV is available for treating COVID-19, while Kevzara addresses rheumatoid arthritis in adults. Regeneron has also made strides in treating Zaire ebolavirus infections through Inmazeb and offers ARCALYST for various periodic syndromes, including familial cold auto-inflammatory syndrome. Furthermore, ZALTRAP is indicated for metastatic colorectal cancer, as the company continually innovates therapies for eye, allergic, inflammatory, cardiovascular, metabolic, infectious, and rare diseases, as well as cancer, pain, and hematologic conditions. The net income ratio stands at 0.31 reflecting the company's profitability margin, while the reported income before tax is 4,779,900,000.00 showcasing its pre-tax profitability. Additionally, the earnings per share (EPS) is reported at $40.90 indicating the company's profitability on a per-share basis. The company earned an interest income of $711,400,000.00 showcasing its financial investments. With a large market capitalization of $68,184,798,840.00 Regeneron is a dominant player in the biopharmaceutical industry, contributing significantly to the overall market landscape. The stock is priced at $634.55 positioning it in the higher-end market, and it has an average trading volume of 942,768.00 indicating moderate liquidity. As a key player in the Biotechnology industry, Regeneron drives innovation and growth, establishing its presence in the Healthcare sector. The company's collaborative efforts through various agreements with notable partners and institutions further reinforce its strategic positioning and commitment to advancing healthcare solutions.
What is Regeneron Pharmaceuticals, Inc. (REGN)'s stock forecast?
Analysts predict Regeneron Pharmaceuticals, Inc. stock to fluctuate between $618.51 (low) and $1,211.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Regeneron Pharmaceuticals, Inc.'s market capitalization?
As of 2025-04-01, Regeneron Pharmaceuticals, Inc.'s market cap is $68,184,798,840, based on 107,508,000 outstanding shares.
How does Regeneron Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Regeneron Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Regeneron Pharmaceuticals, Inc. (REGN) stock?
To buy Regeneron Pharmaceuticals, Inc. (REGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for REGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Regeneron Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Regeneron Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $14,202,000,000 | EPS: $40.90 | Growth: 10.39%.
Where can I find Regeneron Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.regeneron.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Regeneron Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Regeneron Pharmaceuticals, Inc. stock?
All-time high: $1,211.20 (2024-08-27) | All-time low: $441 (2021-03-04).
What are the key trends affecting Regeneron Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
youtube.com
Regeneron CEO Leonard Schleifer on Tuesday said that Health and Human Services Secretary Robert F. Kennedy Jr.
globenewswire.com
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils
globenewswire.com
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) prior to November 2023 and continue to hold any of those NASDAQ: REGN shares, should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
seekingalpha.com
Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led to increased competition and pricing pressures, impacting the company's revenue and profit margins. Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation.
prnewswire.com
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Matteo Paz, 18, of Pasadena, California , won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.'s oldest and most prestigious science and math competition for high school seniors.
globenewswire.com
$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition $250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition
seekingalpha.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET Company Participants Ryan Crowe - SVP, IR & Strategic Analysis Chris Fenimore - CFO Conference Call Participants David Risinger - Leerink Partners David Risinger All right. So we're going to get started.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135096&wire=1 or contact Joseph E. Levi, Esq.
globenewswire.com
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline.
globenewswire.com
Investors can contact the law firm at no cost to learn more about recovering their losses
See all news
